---
title: "China Resources Pharmaceutical Group Ltd. hielt außerordentliche Hauptversammlung ab"
description: "China Resources Pharmaceutical Group Ltd. held an extraordinary general meeting on February 6, 2026. The proposed items, including the approval of ongoing connected transactions under the Sales Framew"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275138791.md"
published_at: "2026-02-06T14:19:40.000Z"
---

# China Resources Pharmaceutical Group Ltd. hielt außerordentliche Hauptversammlung ab

> China Resources Pharmaceutical Group Ltd. held an extraordinary general meeting on February 6, 2026. The proposed items, including the approval of ongoing connected transactions under the Sales Framework Agreement 2026/2028 and amendments to the articles of association, were each approved.

China Resources Pharmaceutical Group Ltd. hat am 6. Februar 2026 eine außerordentliche Hauptversammlung abgehalten. Die vorgeschlagenen Punkte – die Genehmigung fortlaufender verbundener Transaktionen im Rahmen des Sales Framework Agreement 2026⁄2028 sowie die Änderungen der Satzung – wurden jeweils angenommen. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12018532), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md)
- [588860.CN - ICBCCS SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588860.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |
| Beijing Tong Ren Tang Chinese Medicine Co. Ltd. Held Extraordinary General Meeting | Beijing Tong Ren Tang Chinese Medicine Co. Ltd. held an extraordinary general meeting on February 11, 2026, where all pr | [Link](https://longbridge.com/en/news/275583242.md) |
| WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink | WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not alr | [Link](https://longbridge.com/en/news/275670240.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.